Summary
Grail’s Galleri test looks for 50 cancers from a blood draw, but a major study failed to prove it could detect later-stage cancers.
FDA advisers are reviewing a multicancer-detection test. Medicare coverage could follow.
Source & full coverage: this summary is aggregated from MarketWatch, the original publisher. Read the complete report for full context, data and quotes.
Read the original report at MarketWatch →
